Obesity rates in fatty liver disease (MASLD)
Part of Digestive system, Hormones & metabolism clinical trials.
This study looks at how common obesity is in people with a type of fatty liver disease called MASLD. If you have fatty liver and are overweight, this trial may help doctors understand the link between the two conditions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with fatty liver disease (based on a physical exam, blood tests, or imaging).
- You are not pregnant.
- You do not have any active cancer.
- You do not have type 1 diabetes.
- You are not currently taking statins or other fatty liver medications.
- You have not had weight loss surgery (bariatric surgery).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses routine blood tests to find people with advanced liver scarring caused by a condition called MASLD. If you are between 50 and 75, have certain metabolic risks, and get blood work from your primary care doctor at select centers, you may be eligible.
This study looks at how the liver responds to sugar given through a vein in obese patients with and without a fatty liver condition called MASLD. It may help doctors understand why some people develop liver problems from sugar and fat.
This study looks at whether the natural chemicals made by your gut bacteria from the food you eat could affect liver fat and health. If you have MASLD (a fatty liver condition), researchers want to measure these gut-produced substances to better understand the disease.
This study aims to understand the genetic factors behind metabolic fatty liver disease (MASLD) by comparing patients with advanced liver scarring or liver cancer to healthy blood donors. It may help doctors better predict and treat the disease in the future.
This study looks at a new non-invasive screening method to predict metabolic dysfunction–associated steatotic liver disease (MASLD), a condition where fat builds up in the liver. The goal is to help identify people who may be at risk without needing invasive tests.
This study uses a special ultrasound device called FibroScan to check for fatty liver disease (MASLD) in people with obesity who are planning to have weight-loss surgery. The results will be compared to a liver biopsy to see how well the device works.
Hear when a new Lean MASLD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.